CAIV-T Research and Development Sample Clauses

CAIV-T Research and Development. Notwithstanding anything to the contrary regarding allocation of research and development costs set forth in the U.S. Agreement or the International Agreement, the parties agree that they will share certain expenses for the research and development of a liquid trivalent cold-adapted intranasal influenza vaccine (“CAIV-T”) in accordance with the terms of this Section 3. In exchange, each party agrees that it has a continuing obligation to provide to the other all data and other materials related to all studies, trials and tests related to the research and development of CAIV-T (whether completed, on-going or proposed and domestic or international). The parties agree that the design and execution of all studies, trials and tests related to CAIV-T that have either not been initiated as of the date of execution of this Master Amendment or have been initiated but are subsequently modified will be reviewed and agreed upon by the JDC and then submitted to the JCC for final review and approval.
Sample 1Sample 2
AutoNDA by SimpleDocs

Related to CAIV-T Research and Development

  • Research and Development (i) Advice and assistance in relation to research and development of Party B;

  • Clinical Development (a) Stellartech shall design, develop and construct a Clinical Unit for each of the Thermage Disposable Device and the Thermage Generator, and any required component or subassembly thereof and shall deliver such Clinical Units to Thermage in accordance with the Development Program; (b) Stellartech shall deliver to Thermage such other Deliverables as are contemplated by the Development Program in accordance with the Development Program; and (c) as requested by Thermage and automatically at the conclusion of the Development Program, Stellartech, so long as Thermage is not in breach of its material obligation hereunder, shall deliver in writing to Thermage any and all data and information held by or in the control of Stellartech which is necessary or useful to obtain regulatory approval of the Products in the United States or any foreign country.

  • Joint Development All inventions, know-how, trade secrets, data or information which result from joint development by the Parties hereto shall be jointly owned by the Parties. The Parties hereby agree to cooperate in good faith in the filing of any and all patent applications in all jurisdictions.

  • Creation and Development Fee If the Prospectus related to a Trust specifies a creation and development fee, the Trustee shall, on or immediately after the end of the initial offering period, withdraw from the Capital Account, an amount equal to the unpaid creation and development fee as of such date and credit such amount to a special non-Trust account designated by the Depositor out of which the creation and development fee will be distributed to the Depositor (the "Creation and Development Account"). The creation and development fee is the per unit amount specified in the Prospectus for the Trust.

  • Business Development Provide advice and assistance in business growth and development of Party B. 业务发展。对乙方的业务发展提供建议和协助。

  • Business Development Company Buyer is a business development company as defined in Section 202(a)(22) of the Investment Advisors Act of 1940.

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

  • Development 3.1.1 Licensee agrees to and warrants that:

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Strategic Planning The Practice Advisory Council may make recommendations to the Practice concerning development of long-term strategic planning objectives for the Practice.

Time is Money Join Law Insider Premium to draft better contracts faster.